Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir vs Efavirenz in HIV-Infected Pregnant Women
NCT01618305Phase 4Completed
- Sponsor
- Westat
- Start
- Sep 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Westat. Primary endpoints: Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery, Proportion of Participants Who Discontinued Randomized Study Drug Prior to Labor and Delivery and 2 more. Started Sep 2013; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01618305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618305.